Stocks News

LAST PRICE
46.2200
TODAY'S CHANGE (%)
Trending Down-2.7800 (-5.6735%)

Bid / Lots
46.1900/ 10
Ask / Lots
46.2500/ 8
Open / Previous Close
49.2900 / 49.0000
Day Range
Low 45.6400
High 49.3600
52 Week Range
Low 12.2800
High 51.6100
Volume
765,857
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Nov 11, 2024
- Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), from 4:05PM ET on Monday Nov 11, 2024 by Dow Jones
  4:05PM ET on Monday Nov 11, 2024 by Dow Jones
  Companies Mentioned: VERA
  
  Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  
  Brisbane, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on November 4, 2024, the Compensation Committee granted inducement awards consisting of a non-qualified stock option to purchase 54,050 shares of Class A common stock and restricted stock units (RSUs) for 27,025 shares of Class A common stock to seven new employees under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4).
- Vera Therapeutics Partners with University of Michigan on the NEPTUNE Match Project and PIONEER Study, from 8:00AM ET on Monday Nov 11, 2024 by Dow Jones
  8:00AM ET on Monday Nov 11, 2024 by Dow Jones
  Companies Mentioned: VERA
  
  Vera Therapeutics Partners with University of Michigan on the NEPTUNE Match Project and PIONEER Study
  -- Participants with nephrotic syndrome in NEPTUNE Match will receive information about the PIONEER study and other clinical trials based on their individual disease characteristics; -- PIONEER study expands the investigation of atacicept into multiple autoimmune glomerular diseases, supported by the disease-modifying potential of BAFF/APRIL dual inhibition;
Nov 8, 2024
- Vera Therapeutics to Participate at Upcoming Investor Conferences, from 4:05PM ET on Friday Nov 08, 2024 by Dow Jones
  4:05PM ET on Friday Nov 08, 2024 by Dow Jones
  Companies Mentioned: VERA
  
  Vera Therapeutics to Participate at Upcoming Investor Conferences
  
  BRISBANE, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company's management team will present and participate in one-on-one meetings at upcoming investor conferences.
- DJ Vera Therapeutics Is Maintained at Neutral by Wedbush, from 10:21AM ET on Friday Nov 08, 2024 by Dow Jones
  10:21AM ET on Friday Nov 08, 2024 by Dow Jones
  Companies Mentioned: VERA
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/VERA/analyst-ratings
  
  (END) Dow Jones Newswires
  
  November 08, 2024 10:21 ET (15:21 GMT)
- Vera Therapeutics to Participate at Upcoming Investor Conferences, from 8:00AM ET on Friday Nov 08, 2024 by Dow Jones
  8:00AM ET on Friday Nov 08, 2024 by Dow Jones
  Companies Mentioned: VERA
  
  Vera Therapeutics to Participate at Upcoming Investor Conferences
  
  BRISBANE, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company's management team will present and participate in one-on-one meetings at upcoming investor conferences.

Nov 13, 2024
- DJ Dyne Therapeutics Is Maintained at Buy by Chardan Capital, from 6:43PM ET on Wednesday Nov 13, 2024 by Dow Jones
  6:43PM ET on Wednesday Nov 13, 2024 by Dow Jones
  Companies Mentioned: DYN
- DJ Dyne Therapeutics Price Target Maintained With a $55.00/Share by HC Wainwright & Co., from 9:45AM ET on Wednesday Nov 13, 2024 by Dow Jones
  9:45AM ET on Wednesday Nov 13, 2024 by Dow Jones
  Companies Mentioned: DYN
Nov 12, 2024
- Dyne Therapeutics' Q3 Loss Narrows, from 9:11AM ET on Tuesday Nov 12, 2024 by MT Newswires
  9:11AM ET on Tuesday Nov 12, 2024 by MT Newswires
  Companies Mentioned: DYN
- Apogee Therapeutics' Q3 Net Loss Widens, from 8:45AM ET on Tuesday Nov 12, 2024 by MT Newswires
  8:45AM ET on Tuesday Nov 12, 2024 by MT Newswires
  Companies Mentioned: APGE
- Dyne Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update, from 7:30AM ET on Tuesday Nov 12, 2024 by Dow Jones
  7:30AM ET on Tuesday Nov 12, 2024 by Dow Jones
  Companies Mentioned: DYN
- *DJ Dyne Therapeutics 3Q Loss/Shr 96c >DYN, from 7:30AM ET on Tuesday Nov 12, 2024 by Dow Jones
  7:30AM ET on Tuesday Nov 12, 2024 by Dow Jones
  Companies Mentioned: DYN
- Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2024 Financial Results, from 7:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
  7:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
  Companies Mentioned: APGE
- Press Release: Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2024 Financial Results, from 7:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
  7:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
  Companies Mentioned: APGE
Nov 8, 2024
- DJ Edgewise Therapeutics Is Maintained at Outperform by Wedbush, from 10:36AM ET on Friday Nov 08, 2024 by Dow Jones
  10:36AM ET on Friday Nov 08, 2024 by Dow Jones
  Companies Mentioned: EWTX
- RBC Capital Adjusts Edgewise Therapeutics Price Target to $44 From $42, Maintains Outperform, Speculative Risk Rating, from 9:57AM ET on Friday Nov 08, 2024 by MT Newswires
  9:57AM ET on Friday Nov 08, 2024 by MT Newswires
  Companies Mentioned: EWTX

Vera Therapeutics Inc
NASDAQ:VERAUnited States

Search Criteria

Nov 11, 2024

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), from 4:05PM ET on Monday Nov 11, 2024 by Dow Jones

Vera Therapeutics Partners with University of Michigan on the NEPTUNE Match Project and PIONEER Study, from 8:00AM ET on Monday Nov 11, 2024 by Dow Jones

Nov 8, 2024

Vera Therapeutics to Participate at Upcoming Investor Conferences, from 4:05PM ET on Friday Nov 08, 2024 by Dow Jones

DJ Vera Therapeutics Is Maintained at Neutral by Wedbush, from 10:21AM ET on Friday Nov 08, 2024 by Dow Jones

Vera Therapeutics to Participate at Upcoming Investor Conferences, from 8:00AM ET on Friday Nov 08, 2024 by Dow Jones

Peers Headlines

Nov 13, 2024

DJ Dyne Therapeutics Is Maintained at Buy by Chardan Capital, from 6:43PM ET on Wednesday Nov 13, 2024 by Dow Jones

DJ Dyne Therapeutics Price Target Maintained With a $55.00/Share by HC Wainwright & Co., from 9:45AM ET on Wednesday Nov 13, 2024 by Dow Jones

Nov 12, 2024

Dyne Therapeutics' Q3 Loss Narrows, from 9:11AM ET on Tuesday Nov 12, 2024 by MT Newswires

Apogee Therapeutics' Q3 Net Loss Widens, from 8:45AM ET on Tuesday Nov 12, 2024 by MT Newswires

Dyne Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update, from 7:30AM ET on Tuesday Nov 12, 2024 by Dow Jones

*DJ Dyne Therapeutics 3Q Loss/Shr 96c >DYN, from 7:30AM ET on Tuesday Nov 12, 2024 by Dow Jones

Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2024 Financial Results, from 7:00AM ET on Tuesday Nov 12, 2024 by Dow Jones

Press Release: Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2024 Financial Results, from 7:00AM ET on Tuesday Nov 12, 2024 by Dow Jones

Nov 8, 2024

DJ Edgewise Therapeutics Is Maintained at Outperform by Wedbush, from 10:36AM ET on Friday Nov 08, 2024 by Dow Jones

RBC Capital Adjusts Edgewise Therapeutics Price Target to $44 From $42, Maintains Outperform, Speculative Risk Rating, from 9:57AM ET on Friday Nov 08, 2024 by MT Newswires